Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Cytodyn Inc (CYDY)

Cytodyn Inc (CYDY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Bruce Patterson, M.D., Director Candidate for CytoDyn Board, Presents at International COVID Summit

A group of long-time stockholders (the "Nominating Stockholders") of CytoDyn Inc. ("CYDY or the "Company") (OTC: CYDY) that has nominated five highly experienced director candidates to serve on the Company's...

CYDY : 2.0100 (+22.56%)
Glancy Prongay & Murray LLP Announces Investigation of CytoDyn Inc.

Glancy Prongay & Murray LLP ("GPM") announces its investigation of CytoDyn Inc. (OTCQB:CYDY) concerning the Company and its directors' and officers' possible violations of state laws.

CYDY : 2.0100 (+22.56%)
Why Experts Believe Antibody Treatments Hold The Potential To Reduce Need For Hospitalization For COVID-19 Patients - Financial News Media

Palm Beach, FL - September 14, 2021 – FinancialNewsMedia.com News Commentary – All across the globe, innumerable scientists are looking to beat COVID-19... the two main paths are to find better vaccines...

BIOV.CN : 0.540 (+24.14%)
BVAXF : 0.4236 (+26.07%)
SRNE : 8.25 (+2.10%)
BNTX : 359.18 (-3.61%)
CYDY : 2.0100 (+22.56%)
NVAX : 237.54 (+0.11%)
Why Experts Believe Antibody Treatments Hold The Potential To Reduce Need For Hospitalization For COVID-19 Patients

/PRNewswire/ --  - All across the globe, innumerable scientists are looking to beat COVID-19… the two main paths are to find better vaccines and to utilize better treatments. As with most viruses, developing...

BIOV.CN : 0.540 (+24.14%)
BVAXF : 0.4236 (+26.07%)
SRNE : 8.25 (+2.10%)
BNTX : 359.18 (-3.61%)
CYDY : 2.0100 (+22.56%)
NVAX : 237.54 (+0.11%)
CytoDyn to Present at Emerging Growth Conference on September 15 Follow by Live Q/A

CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today...

CYDY : 2.0100 (+22.56%)
CytoDyn Announces Treatment of the First Patient in its Pivotal Phase 3 COVID-19 Trial in Brazil for Patients with Severe Symptoms

An interim analysis will be conducted 28 days following enrollment of 245 patients (40% of targeted trial patients)

CYDY : 2.0100 (+22.56%)
Group of CytoDyn Stockolders Responds to Misleading Company News Release

A group of long-time stockholders (the "Nominating Stockholders") of CytoDyn Inc. ("CYDY" or the "Company") (OTC: CYDY) that has nominated five highly experienced director candidates to serve on the Company's...

CYDY : 2.0100 (+22.56%)
CytoDyn to Hold Webcast on September 8 to Discuss Results from mTNBC Trials, HIV BLA Status, and Updates on COVID-19 and NASH Trials

CytoDyn Inc. (OTCQB: CYDY), ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced...

CYDY : 2.0100 (+22.56%)
CytoDyn Highlights Court Ordering Rosenbaum/Patterson Group to Comply With the Federal Securities Laws

--Continues Pattern by Rosenbaum/Patterson Group of Eschewing Transparency, Misleading Shareholders and Ignoring Proxy Rules

CYDY : 2.0100 (+22.56%)
Group of CytoDyn Stockholders Warns Stockholders of Board's Continued Value Destruction and Failures

--Urges Stockholders to Vote on the WHITE Proxy Card Today to Elect Group's Five Highly Experienced Director Nominees to Effect Sorely Needed Change and Begin to Generate Much-Needed Revenue

CYDY : 2.0100 (+22.56%)

Barchart Exclusives

US Stock Markets: Stop the Seasonal Madness
A popular theme on financial television these days is September is a seasonally bearish time for US stock markets. The evidence does not support this idea. Read more

Barchart Futures Commentary

Barchart Futures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar